Clinical experience with angiotensin II receptor antagonists

Details

Serval ID
serval:BIB_6E7084855082
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Clinical experience with angiotensin II receptor antagonists
Journal
American Journal of Hypertension
Author(s)
Brunner  H. R., Christen  Y., Munafo  A., Lee  R. J., Waeber  B., Nussberger  J.
ISSN
0895-7061 (Print)
Publication state
Published
Issued date
12/1992
Volume
5
Number
12 Pt 2
Pages
243S-246S
Notes
Clinical Trial
Controlled Clinical Trial
Journal Article --- Old month value: Dec
Abstract
This series of studies was designed to assess in normal volunteers the relationships between various doses (5, 10, 20, 40, 80, and 120 mg) of the orally active angiotensin II antagonist losartan (DuP 753, MK-954) and their inhibitory effect on the pressure response to a given bolus of angiotensin I or II. It was found that the maximal inhibitory effect was reached with a dose of 80 mg. The minimal dose necessary for maximal efficacy would therefore be expected to be between 40 and 80 mg. The effect lasted for more than 24 h and was related almost exclusively to the circulating levels of the active metabolite EXP3174. It remains to be demonstrated in hypertensive patients that the same dose relationship holds for the antihypertensive effect, but preliminary data already suggest that this is the case.
Keywords
Administration, Oral Angiotensin I/administration & dosage/pharmacology Angiotensin II/administration & dosage/antagonists & inhibitors/pharmacology Antihypertensive Agents/administration & dosage/adverse effects/therapeutic use Biphenyl Compounds/administration & dosage/adverse effects/*therapeutic use Blood Pressure/drug effects/physiology Dose-Response Relationship, Drug Humans Hypertension/blood/drug therapy/physiopathology Imidazoles/administration & dosage/adverse effects/blood/*therapeutic use Injections, Intravenous Losartan Receptors, Angiotensin/*antagonists & inhibitors Renin-Angiotensin System/drug effects/physiology Tetrazoles/administration & dosage/adverse effects/blood/*therapeutic use Time Factors
Pubmed
Web of science
Create date
05/03/2008 16:41
Last modification date
20/08/2019 14:27
Usage data